|
|
|
|
|
30.03.26 - 13:36
|
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update (Business Wire)
|
|
|
Faeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway
$200 million private placement supports key clinical milestones in endometrial and breast cancerBOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the full year ended December 31, 2025, following its previously announced acquisition of Faeth Therapeutics and concurrent $200 million private placement. The financing, together with the Company's cash on hand, is expected to support advancement of PIKTOR through key clinical milestones, including topline data readouts from both the ongoing Phase 2 trial in advanced endometrial cancer (Study FTH-PIK-201) and the planned Phase 1b trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101).
Acquired through the Faeth transaction, PIKTOR is now Sensei's lead program. The investigational, proprietary, all-oral combination of serabelisib and sapanisertib is designed to inhibit multi...
|
|
|
17.03.26 - 11:03
|
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on March 11, 2026, Sensei's Board of Directors granted a new employee an option to purchase 166,435 shares of the Company's common stock in connection with their employment (collectively, the “Option Award”). The Option Award was granted as an inducement material to the individual entering employment with Sensei in accordance with Nasdaq Listing Rule 5635(c)(4).
The Option Award has an exercise price of $29.37, which is equal to the closing price of Sensei's common stock on March 11, 2026, and will vest, with respect to 25% of the shares subject to each such award, on the first anniversary of the date of grant, with the remaining shares vesting in equal monthly installments over a three-year period, in each case subject to such employee's continued service with Sensei through each such vesting date.
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical-stage biotech...
|
|
|
25.02.26 - 12:06
|
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Sensei's Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893 shares of the Company's common stock in connection with their employment, including a grant to Anand Parikh of an option to purchase 1,239,305 shares of the Company's common stock in connection with his employment as Chief Operating Officer of the Company (collectively, the “Option Awards”). The Option Awards were granted as an inducement material to the individuals entering employment with Sensei in accordance with Nasdaq Listing Rule 5635(c)(4).
The Option Awards have an exercise price of $27.22, which is equal to the closing price of Sensei's common stock on February 19, 2026, and will vest, with respect to 25% of the shares subject to each such award, on the first anniversary of the date of grant, with the remaining shares vesting in equal monthly installments over a three...
|
|
|
19.02.26 - 10:15
|
Sensei Biotherapeutics: NBC-Tipp liefert +282% in 8 Handelstagen (Sharedeals)
|
|
|
Reihenweise Multibagger konnten Mitglieder des No Brainer Club in den vergangenen Monaten feiern. Mit der Aktie von Sensei Biotherapeutics gesellt sich ein Bonus-Tipp dem Track Record hinzu. Was ist passiert? NBC-Chefanalyst Maximilian Ruth hatte die Aktie von Sensei seit Oktober letzten Jahres unter genauerer Beobachtung. Der Krebsforscher hatte zu diesem Zeitpunkt eine umfassende strategische Überprüfung […]
The post Sensei Biotherapeutics: NBC-Tipp liefert +282% in 8 Handelstagen first appeared on sharedeals.de....
|
|
|
|
|
|
|
18.02.26 - 14:06
|
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement (Business Wire)
|
|
|
Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer
PIKTOR is an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway in development across solid tumor settings, including endometrial and breast cancer
Sensei to host an audio-only conference call and webcast today, February 18, 2026, at 8:30 a.m. ETBOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. (“Faeth”), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The acquisition brings Faeth's lead asset PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, into Sensei's pipeline.
Concurrent with the acquisition, Sens...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.10.25 - 14:03
|
Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value (GlobeNewswire EN)
|
|
|
BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that its Board of Directors has determined, after extensive consideration of the Company's development pipeline and current market conditions, to discontinue development of solnerstotug and initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. The Company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the Company, a business combination, a merger, or an orderly wind-down of operations....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
